DOI:
10.1055/s-00000097
Deutsche Zeitschrift für Onkologie
LinksClose Window
References
Motzer RJ. et al.
RAD001 vs placebo in patients with metastatic renal cell
carcinoma after progression on VEGFr-TKI therapy: results from a randomized,
double bind multicenter phase III study.
J Clin Oncol 2008; 26: LBA5026-
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.